Sevim Erdem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sevim Erdem has a total of 850 co-authors. Here are the top co-authors by number of shared publications:
Ersin Tan
Department of Neurology, Hacettepe University, School of Medicine, Ankara, Turkey
20 shared publications- Can Ebru Bekircan-Kurt
Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkiye
15 shared publications - Ersin Tan
Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkiye
10 shared publications - Mehmet Demirci
Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
6 shared publications Haluk Topaloglu
Department of Pediatric Neurology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey
5 shared publicationsCan Ebru Bekircan-Kurt
4 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 32 (3) , 230-236
Increased epidermal growth factor expression in amyotrophic lateral sclerosis patients: A potential protective mechanism against pressure ulcers
Objectives: This study aimed to investigate epidermal growth factor (EGF) and keratinocyte growth factor (KGF) expression in proximal (gluteal) and distal (ankle) skin biopsies of individuals diagnosed with amyotrophic lateral sclerosis (ALS) compared to controls and to explore whether these factors may contribute to the relative sparing of pressure ulcers in ALS. Patients and methods: In this prospective cohort study, 10 patients with limb-onset ALS and 16 age- and sex-matched controls with other neurological diseases underwent skin biopsies between April 2015 and December 2016. Immunohistochemical staining for EGF, KGF, and PGP9.5 was performed. Growth-factor expression was semiquantitatively scored; intraepidermal nerve fiber density quantification followed established protocol. Results: The ALS group (7 male, 3 female; mean age: 52.9 ± 13.5 years; range, 31 to 72 years) and the control group (10 male, 6 female; mean age: 51.8 ± 12.8 years; range, 29 to 73 years) had similar demographic characteristics ( p > 0.05). Proximal EGF expression was significantly higher in patients with ALS ( p < 0.05). Distal EGF expression did not differ between groups. Across all participants, proximal EGF levels were higher compared to distal levels ( p < 0.05). Expression of KGF showed no intergroup difference at either anatomical biopsy site. Patients with ALS demonstrated reduced intraepidermal nerve fiber density both in proximal and distal samples compared to established normative values consistent with small-fiber involvement. No associations were found between EGF and KGF levels and age, sex, or disease duration. Conclusion: Increased EGF expression in pressure-prone gluteal skin of patients with ALS suggests that EGF-mediated wound-healing pathways may contribute to the unexpectedly low incidence of pressure ulcers in ALS. Larger prospective studies incorporating biochemical, histological, and functional assays are required to establish the mechanistic basis of this growth factor dysregulation in ALS.
- 1 September 2026
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 32 (3) , 230-236
Open AccessIncreased epidermal growth factor expression in amyotrophic lateral sclerosis patients: A potential protective mechanism against pressure ulcers
Objectives: This study aimed to investigate epidermal growth factor (EGF) and keratinocyte growth factor (KGF) expression in proximal (gluteal) and distal (ankle) skin biopsies of individuals diagnosed with amyotrophic lateral sclerosis (ALS) compared to controls and to explore whether these factors may contribute to the relative sparing of pressure ulcers in ALS. Patients and methods: In this prospective cohort study, 10 patients with limb-onset ALS and 16 age- and sex-matched controls with other neurological diseases underwent skin biopsies between April 2015 and December 2016. Immunohistochemical staining for EGF, KGF, and PGP9.5 was performed. Growth-factor expression was semiquantitatively scored; intraepidermal nerve fiber density quantification followed established protocol. Results: The ALS group (7 male, 3 female; mean age: 52.9 ± 13.5 years; range, 31 to 72 years) and the control group (10 male, 6 female; mean age: 51.8 ± 12.8 years; range, 29 to 73 years) had similar demographic characteristics ( p > 0.05). Proximal EGF expression was significantly higher in patients with ALS ( p < 0.05). Distal EGF expression did not differ between groups. Across all participants, proximal EGF levels were higher compared to distal levels ( p < 0.05). Expression of KGF showed no intergroup difference at either anatomical biopsy site. Patients with ALS demonstrated reduced intraepidermal nerve fiber density both in proximal and distal samples compared to established normative values consistent with small-fiber involvement. No associations were found between EGF and KGF levels and age, sex, or disease duration. Conclusion: Increased EGF expression in pressure-prone gluteal skin of patients with ALS suggests that EGF-mediated wound-healing pathways may contribute to the unexpectedly low incidence of pressure ulcers in ALS. Larger prospective studies incorporating biochemical, histological, and functional assays are required to establish the mechanistic basis of this growth factor dysregulation in ALS.
- Open Access
- 31 December 2025
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 56, 6-11
Clinical and electrophysiological features of Guillain-Barré syndrome: A 7-year experience of Hacettepe University Department of Neurology
Objective: Guillain-Barré Syndrome (GBS) is the most common cause of severe acute paralytic neuropathy. In this retrospective study, we present the GBS experience of the Hacettepe University Department of Neurology and discuss the clinical and electrophysiological features. Material and Methods: Demographic data, presenting complaints, cerebrospinal fluid (CSF) findings, EMG results, and treatments of patients with electrophysiological findings compatible with GBS between August 2017 and August 2024 were retrospectively reviewed. Results: Fifty-nine patients diagnosed with GBS (41 males, mean [min-max] age 49 [3–92] years) were recorded. Among them, 66% (n=39) were classified as AIDP, 22% (n=13) as AMAN, 3% (n=2) as AMSAN, and 9% (n=5) as MFS. It was noted that EMG was performed within an average of 11 days after the onset of the first symptom. Sensory complaints were the initial symptoms in half of the patients. Six patients (10%) required mechanical ventilation during follow-up. Prolonged or absent F-waves in one or more nerves were recorded in 64% (n=38) of upper limbs and %90 (n=53) of lower limbs. Reduced distal compound muscle action potentials (CMAP) in two or more nerves were observed in 51 patients (86%), prolonged distal motor latency (DML) in two or more nerves in 40 patients (68%) and slowed motor nerve conduction velocities (NCV) in two or more nerves in 26 patients (44%). Sural SNAP amplitudes were normal in 33 patients (56%), decreased in 14 (24%), and absent in 12 (20%). The conduction block was recorded in 10 patients (17%), and temporal dispersion was noted in 19 patients (32%). Treatment included IVIg in 40 patients (68%) and plasmapheresis in 2 (3%), and due to insufficient treatment response, the number of patients requiring plasmapheresis after IVIg or vice versa was 13 (22%). Conclusion: This study showed that AIDP is the most common electrophysiological subtype of GBS in our population. Our study found that AIDP was GBS’s most common electrophysiological subtype. Prolonged or absent F-waves reduced distal CMAP amplitudes, prolonged DML, slowed NCV, decreased upper limb SNAP amplitudes, and partially preserved sural sensory responses observed in our study were consistent with the findings of other studies.
- 31 December 2025
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 56, 6-11
Open AccessClinical and electrophysiological features of Guillain-Barré syndrome: A 7-year experience of Hacettepe University Department of Neurology
Objective: Guillain-Barré Syndrome (GBS) is the most common cause of severe acute paralytic neuropathy. In this retrospective study, we present the GBS experience of the Hacettepe University Department of Neurology and discuss the clinical and electrophysiological features. Material and Methods: Demographic data, presenting complaints, cerebrospinal fluid (CSF) findings, EMG results, and treatments of patients with electrophysiological findings compatible with GBS between August 2017 and August 2024 were retrospectively reviewed. Results: Fifty-nine patients diagnosed with GBS (41 males, mean [min-max] age 49 [3–92] years) were recorded. Among them, 66% (n=39) were classified as AIDP, 22% (n=13) as AMAN, 3% (n=2) as AMSAN, and 9% (n=5) as MFS. It was noted that EMG was performed within an average of 11 days after the onset of the first symptom. Sensory complaints were the initial symptoms in half of the patients. Six patients (10%) required mechanical ventilation during follow-up. Prolonged or absent F-waves in one or more nerves were recorded in 64% (n=38) of upper limbs and %90 (n=53) of lower limbs. Reduced distal compound muscle action potentials (CMAP) in two or more nerves were observed in 51 patients (86%), prolonged distal motor latency (DML) in two or more nerves in 40 patients (68%) and slowed motor nerve conduction velocities (NCV) in two or more nerves in 26 patients (44%). Sural SNAP amplitudes were normal in 33 patients (56%), decreased in 14 (24%), and absent in 12 (20%). The conduction block was recorded in 10 patients (17%), and temporal dispersion was noted in 19 patients (32%). Treatment included IVIg in 40 patients (68%) and plasmapheresis in 2 (3%), and due to insufficient treatment response, the number of patients requiring plasmapheresis after IVIg or vice versa was 13 (22%). Conclusion: This study showed that AIDP is the most common electrophysiological subtype of GBS in our population. Our study found that AIDP was GBS’s most common electrophysiological subtype. Prolonged or absent F-waves reduced distal CMAP amplitudes, prolonged DML, slowed NCV, decreased upper limb SNAP amplitudes, and partially preserved sural sensory responses observed in our study were consistent with the findings of other studies.
- Open Access
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1475-1479
Diagnostic yield of clinical exome sequencing in patients with suspected hereditary neuropathy
Background/aim: Hereditary neuropathies exhibit significant genetic heterogeneities, often making molecular diagnosis challenging. Clinical Exome Sequencing (CES) allows the simultaneous evaluation of a wide range of candidate genes, and can be considered an efficient approach to identifying underlying genetic causes. The present study assesses the diagnostic utility of CES in patients with clinically suspected hereditary neuropathy. Materials and methods: Included in the study were 21 patients with clinically suspected hereditary neuropathy who underwent CES. DNA samples were isolated from peripheral blood and subjected to CES on an Illumina NextSeq 2000 system, while a bioinformatics analysis and variant interpretation were performed using Sophia DDM® software. All identified variants were classified according to the most recent American College of Medical Genetics and Genomics (ACMG) guidelines. Results: Pathogenic or likely pathogenic variants were identified in seven patients (33.3%), of whom six (28.5%) had a confirmed molecular diagnosis consistent with the clinical phenotype. Variants of uncertain significance (VUS) were detected in nine patients (42.8%), while no clinically relevant variants were found in five (23.8%). Conclusion: CES contributed significantly to the establishment of molecular diagnoses in nearly one-third of the studied cohort. However, the high prevalence of VUS underscores the limitations of current interpretation frameworks, revealing a need for functional validation and familial segregation analyses. Despite these challenges, CES remains a valuable and appropriate diagnostic tool, particularly in resource-limited healthcare settings.
- 12 December 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1475-1479
Open AccessDiagnostic yield of clinical exome sequencing in patients with suspected hereditary neuropathy
Background/aim: Hereditary neuropathies exhibit significant genetic heterogeneities, often making molecular diagnosis challenging. Clinical Exome Sequencing (CES) allows the simultaneous evaluation of a wide range of candidate genes, and can be considered an efficient approach to identifying underlying genetic causes. The present study assesses the diagnostic utility of CES in patients with clinically suspected hereditary neuropathy. Materials and methods: Included in the study were 21 patients with clinically suspected hereditary neuropathy who underwent CES. DNA samples were isolated from peripheral blood and subjected to CES on an Illumina NextSeq 2000 system, while a bioinformatics analysis and variant interpretation were performed using Sophia DDM® software. All identified variants were classified according to the most recent American College of Medical Genetics and Genomics (ACMG) guidelines. Results: Pathogenic or likely pathogenic variants were identified in seven patients (33.3%), of whom six (28.5%) had a confirmed molecular diagnosis consistent with the clinical phenotype. Variants of uncertain significance (VUS) were detected in nine patients (42.8%), while no clinically relevant variants were found in five (23.8%). Conclusion: CES contributed significantly to the establishment of molecular diagnoses in nearly one-third of the studied cohort. However, the high prevalence of VUS underscores the limitations of current interpretation frameworks, revealing a need for functional validation and familial segregation analyses. Despite these challenges, CES remains a valuable and appropriate diagnostic tool, particularly in resource-limited healthcare settings.
- 1 January 2025
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 78 (9-10) , 357-360
Felnőttkori kezdetű dezmin-myopathia sclerosis multiplexes betegnél
A dezmin egy intermedier filamentum, és génjének (DES) mutációja leggyakrabban myofibrillaris myopathiát okoz. Egy 26 éves férfi beteg progresszív proximális izomgyengeséggel jelentkezett, és diagnosztikai kivizsgálásra került. A vizsgálat során a proximális végtaggyengeség mellett a jobb oldali lá tásélesség csökkenése és enyhe felszínes ér zés zavar volt megfigyelhető. A szérumban magas kreatinkinázszint, valamint az elektromiográfián myopathiás eltérések voltak észlelhetők. Az izombiopszia myopathiás elváltozásokat mutatott, dystrophinra pozitív vakuólumokkal és az endomysium enyhe felszaporodásával. Az agyi MR-vizsgálat T2-hiperintenzív laesiókat ábrázolt, részben kontraszthalmozással, amelyek primer demyelinisatiós betegségnek feleltek meg. Az új generációs DNS-szekvenálás a DES-gén homozigóta c.1289-2A>G mutációját mutatta ki, amelyet korábban mindössze egy családban írtak le. Bár központi idegrendszeri érintettség többféle izombetegségben is előfordulhat, a sclerosis multiplex (SM) és a myopathia együttes megjelenése rendkívül ritka. Tudomásunk szerint ez az első eset, amelyben dezminhez kapcsolt myopathia és SM együtt fordul elő.
- 1 January 2025
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 78 (9-10) , 357-360
Felnőttkori kezdetű dezmin-myopathia sclerosis multiplexes betegnél
A dezmin egy intermedier filamentum, és génjének (DES) mutációja leggyakrabban myofibrillaris myopathiát okoz. Egy 26 éves férfi beteg progresszív proximális izomgyengeséggel jelentkezett, és diagnosztikai kivizsgálásra került. A vizsgálat során a proximális végtaggyengeség mellett a jobb oldali lá tásélesség csökkenése és enyhe felszínes ér zés zavar volt megfigyelhető. A szérumban magas kreatinkinázszint, valamint az elektromiográfián myopathiás eltérések voltak észlelhetők. Az izombiopszia myopathiás elváltozásokat mutatott, dystrophinra pozitív vakuólumokkal és az endomysium enyhe felszaporodásával. Az agyi MR-vizsgálat T2-hiperintenzív laesiókat ábrázolt, részben kontraszthalmozással, amelyek primer demyelinisatiós betegségnek feleltek meg. Az új generációs DNS-szekvenálás a DES-gén homozigóta c.1289-2A>G mutációját mutatta ki, amelyet korábban mindössze egy családban írtak le. Bár központi idegrendszeri érintettség többféle izombetegségben is előfordulhat, a sclerosis multiplex (SM) és a myopathia együttes megjelenése rendkívül ritka. Tudomásunk szerint ez az első eset, amelyben dezminhez kapcsolt myopathia és SM együtt fordul elő.
- Open Access
- 1 August 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (6) , 2989-2994
Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis
Background: Increasing data are available on the use and efficacy of rituximab (RTX) in patients with anti-muscle-specific tyrosine kinase (MuSK)-positive myasthenia gravis (MG), especially those steroid-dependent or unresponsive to traditional immunotherapies. Aims: We aimed to evaluate the clinical characteristics and treatment responses of adult patients with generalized anti-MuSK-positive MG treated with RTX. Methods: We retrospectively recruited 16 patients who were on RTX, between January 2010 and September 2023. RTX was given 1000 mg/day intravenously twice, two weeks apart. Maintenance treatment was administered at intervals of 3—6 months based on clinical evaluation. The outcome was assessed by Myasthenia Gravis Foundation of America (MGFA) and Myasthenia Gravis Status and Treatment Intensity (MGSTI) scores. Additionally, anti-MuSK antibody levels were retested after treatment in all patients except one. Results: Twelve patients were female. The mean age at disease onset was 35.3 ± 17.3 years. The median duration between disease onset and RTX administration was 2.4 years (min-max: 0.5-36.5 years). The worst MGFA class before RTX was between IIIb-V. After RTX treatment, 81.3% of patients achieved MGFA minimal manifestations or better and MGSTI level 1 or better. Anti-MuSK antibodies became negative in 12 patients, while they remained positive in three. The changes in antibody levels seemed associated with clinical outcomes. Conclusions: RTX is an effective treatment in anti-MuSK-positive MG. Furthermore, our results support the inhibition of antibody production by RTX and we recommend monitoring anti-MuSK antibody titers to follow disease progression and treatment response.
- 1 August 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (6) , 2989-2994
Open AccessClinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis
Background: Increasing data are available on the use and efficacy of rituximab (RTX) in patients with anti-muscle-specific tyrosine kinase (MuSK)-positive myasthenia gravis (MG), especially those steroid-dependent or unresponsive to traditional immunotherapies. Aims: We aimed to evaluate the clinical characteristics and treatment responses of adult patients with generalized anti-MuSK-positive MG treated with RTX. Methods: We retrospectively recruited 16 patients who were on RTX, between January 2010 and September 2023. RTX was given 1000 mg/day intravenously twice, two weeks apart. Maintenance treatment was administered at intervals of 3—6 months based on clinical evaluation. The outcome was assessed by Myasthenia Gravis Foundation of America (MGFA) and Myasthenia Gravis Status and Treatment Intensity (MGSTI) scores. Additionally, anti-MuSK antibody levels were retested after treatment in all patients except one. Results: Twelve patients were female. The mean age at disease onset was 35.3 ± 17.3 years. The median duration between disease onset and RTX administration was 2.4 years (min-max: 0.5-36.5 years). The worst MGFA class before RTX was between IIIb-V. After RTX treatment, 81.3% of patients achieved MGFA minimal manifestations or better and MGSTI level 1 or better. Anti-MuSK antibodies became negative in 12 patients, while they remained positive in three. The changes in antibody levels seemed associated with clinical outcomes. Conclusions: RTX is an effective treatment in anti-MuSK-positive MG. Furthermore, our results support the inhibition of antibody production by RTX and we recommend monitoring anti-MuSK antibody titers to follow disease progression and treatment response.
- 25 April 2024
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 124 (5) , 1467-1475
Differentiating recurrent Guillain–Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review
Guillain–Barre syndrome (GBS) is an acute-onset immune-mediated polyneuropathy characterized by ascending symmetrical muscle weakness, diminished reflexes, and sensory symptoms. While GBS typically follows a monophasic course, some patients experience treatment-related fluctuations or recurrences, posing diagnostic challenges in distinguishing GBS from acute-onset chronic inflammatory polyneuropathy (A-CIDP). A-CIDP, may present acutely, simulating GBS, with a nadir in less than 8 weeks, subsequently evolving into a chronic or relapsing course. The distinction between recurrent GBS and A-CIDP is crucial, as A-CIDP necessitates long-term immunosuppression. A PubMed search was conducted using the search terms ‘recurrent Guillain Barre syndrome’ and ‘acute onset CIDP’ focusing on studies in the English language, published between January 1, 2004 and April 30, 2023. Overlapping clinical features, particularly in the early stages, complicate differentiation between recurrent GBS and CIDP. Electrophysiological studies, ultrasonography, and immunological markers have been explored for discrimination; however, definitive criteria for differentiation remain elusive. Recent follow-up studies have further blurred the boundaries between recurrent GBS and A-CIDP, suggesting the persistence of underlying immune processes even in GBS patients without clinical deterioration. This emphasizes the necessity of reevaluating diagnostic criteria and treatment strategies. In conclusion, distinguishing recurrent GBS from A-CIDP remains an ongoing challenge. Existing evidence questions the categorization of recurrent GBS as a distinct entity, challenging its very existence. Continued research is necessary to refine diagnostic criteria and deepen our understanding of these conditions, ultimately advancing patient care. This review delves into the intricacies of recurrent GBS and A-CIDP differentiation and highlights the need for a reevaluation of the recurrent GBS concept.
- 25 April 2024
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 124 (5) , 1467-1475
Differentiating recurrent Guillain–Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review
Guillain–Barre syndrome (GBS) is an acute-onset immune-mediated polyneuropathy characterized by ascending symmetrical muscle weakness, diminished reflexes, and sensory symptoms. While GBS typically follows a monophasic course, some patients experience treatment-related fluctuations or recurrences, posing diagnostic challenges in distinguishing GBS from acute-onset chronic inflammatory polyneuropathy (A-CIDP). A-CIDP, may present acutely, simulating GBS, with a nadir in less than 8 weeks, subsequently evolving into a chronic or relapsing course. The distinction between recurrent GBS and A-CIDP is crucial, as A-CIDP necessitates long-term immunosuppression. A PubMed search was conducted using the search terms ‘recurrent Guillain Barre syndrome’ and ‘acute onset CIDP’ focusing on studies in the English language, published between January 1, 2004 and April 30, 2023. Overlapping clinical features, particularly in the early stages, complicate differentiation between recurrent GBS and CIDP. Electrophysiological studies, ultrasonography, and immunological markers have been explored for discrimination; however, definitive criteria for differentiation remain elusive. Recent follow-up studies have further blurred the boundaries between recurrent GBS and A-CIDP, suggesting the persistence of underlying immune processes even in GBS patients without clinical deterioration. This emphasizes the necessity of reevaluating diagnostic criteria and treatment strategies. In conclusion, distinguishing recurrent GBS from A-CIDP remains an ongoing challenge. Existing evidence questions the categorization of recurrent GBS as a distinct entity, challenging its very existence. Continued research is necessary to refine diagnostic criteria and deepen our understanding of these conditions, ultimately advancing patient care. This review delves into the intricacies of recurrent GBS and A-CIDP differentiation and highlights the need for a reevaluation of the recurrent GBS concept.
- 1 January 2024
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 77 (9-10) , 357-360
Recurrent simultaneous central nervous system demyelination with possible peripheral demyelination / nodopathy in a seronegative patient
Combined central and peripheral demyelination (CCPD) is a rare disease entity. Onset with the simultaneous central nervous system (CNS) and peripheral nervous system (PNS) involvement and its recurrence are exceptional. Anti-neurofascin antibodies have been shown to be present in up to 70% of cases, yet seronegative patients also exist. We present a case of seronegative recurrent CCPD. The PNS involvement was compatible with two episodes of recurrent Guillain-Barre syndrome (GBS), whereas the CNS involvement pattern was not typical for either multiple sclerosis (MS) or acute disseminated encephalomyelitis. The prognosis was excellent with pulse methylprednisolone, intravenous immunoglobulin, and plasmapheresis. This case highlights the varied clinical presentations of CCPD, extending beyond the realms of MS and chronic inflammatory demyelinating polyneuropathy, and underscores the potential for relapse. Importantly, to the best of our knowledge, this represents the inaugural instance of CCPD featuring PNS involvement in the form of recurrent GBS.
- 1 January 2024
- Published by Ideggyogyaszati Szemle Journal in Ideggyogyaszati Szemle
- Vol. 77 (9-10) , 357-360
Recurrent simultaneous central nervous system demyelination with possible peripheral demyelination / nodopathy in a seronegative patient
Combined central and peripheral demyelination (CCPD) is a rare disease entity. Onset with the simultaneous central nervous system (CNS) and peripheral nervous system (PNS) involvement and its recurrence are exceptional. Anti-neurofascin antibodies have been shown to be present in up to 70% of cases, yet seronegative patients also exist. We present a case of seronegative recurrent CCPD. The PNS involvement was compatible with two episodes of recurrent Guillain-Barre syndrome (GBS), whereas the CNS involvement pattern was not typical for either multiple sclerosis (MS) or acute disseminated encephalomyelitis. The prognosis was excellent with pulse methylprednisolone, intravenous immunoglobulin, and plasmapheresis. This case highlights the varied clinical presentations of CCPD, extending beyond the realms of MS and chronic inflammatory demyelinating polyneuropathy, and underscores the potential for relapse. Importantly, to the best of our knowledge, this represents the inaugural instance of CCPD featuring PNS involvement in the form of recurrent GBS.
- 20 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (5) , 1229-1236
Comprehensive evaluation of velopharyngeal function in myasthenia gravis patients
Purpose Hypernasality, which is a symptom of dysarthria, may be seen in patients with Myasthenia Gravis with bulbar symptoms. However, there is not enough evidence to show that these patients may have velopharyngeal dysfunction. This study investigates the features of velopharyngeal function in myasthenia gravis patients using objective and subjective measurement tools. Methods Ten adult myasthenia gravis patients with bulbar symptoms and ten adult myasthenia gravis patients without bulbar symptoms were recruited for this study. Ten healthy subjects were also included as the control group. The nasalance scores of the participants were determined using a nasometer. The degree and pattern of velopharyngeal closure were scored using flexible nasoendoscopy during speech, blowing, dry swallowing, and food swallowing. Perceptual hypernasality was assessed. Results Velopharyngeal dysfunction was detected in 50% of the myasthenia gravis patients with bulbar symptoms. Velopharyngeal dysfunction was not seen in myasthenia gravis patients without bulbar symptoms. The degree of velopharyngeal closure in patients with bulbar symptoms differed depending on the tasks being performed. No significant difference in velopharyngeal closure patterns was observed between the groups (p < 0.05). Conclusion Myasthenia gravis patients with bulbar involvement may have velopharyngeal dysfunction. It is important to conduct a comprehensive evaluation to assess all aspects of the velopharyngeal function.
- 20 March 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (5) , 1229-1236
Comprehensive evaluation of velopharyngeal function in myasthenia gravis patients
Purpose Hypernasality, which is a symptom of dysarthria, may be seen in patients with Myasthenia Gravis with bulbar symptoms. However, there is not enough evidence to show that these patients may have velopharyngeal dysfunction. This study investigates the features of velopharyngeal function in myasthenia gravis patients using objective and subjective measurement tools. Methods Ten adult myasthenia gravis patients with bulbar symptoms and ten adult myasthenia gravis patients without bulbar symptoms were recruited for this study. Ten healthy subjects were also included as the control group. The nasalance scores of the participants were determined using a nasometer. The degree and pattern of velopharyngeal closure were scored using flexible nasoendoscopy during speech, blowing, dry swallowing, and food swallowing. Perceptual hypernasality was assessed. Results Velopharyngeal dysfunction was detected in 50% of the myasthenia gravis patients with bulbar symptoms. Velopharyngeal dysfunction was not seen in myasthenia gravis patients without bulbar symptoms. The degree of velopharyngeal closure in patients with bulbar symptoms differed depending on the tasks being performed. No significant difference in velopharyngeal closure patterns was observed between the groups (p < 0.05). Conclusion Myasthenia gravis patients with bulbar involvement may have velopharyngeal dysfunction. It is important to conduct a comprehensive evaluation to assess all aspects of the velopharyngeal function.
- 9 July 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (6) , 1499-1509
Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALS
Skeletal muscle pathology is thought to have an important role in the onset and/or progression of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by progressive muscle weakness. Since miRNAs are recognized as important regulatory factors of essential biological processes, we aimed to identify differentially expressed miRNAs in the skeletal muscle of sporadic ALS patients through the combination of molecular-omic technologies and bioinformatic tools. We analyzed the miRnome profiles of skeletal muscle biopsies acquired from ten sALS patients and five controls with Affymetrix GeneChip miRNA 4.0 Array. To find out differentially expressed miRNAs in patients, data were analyzed by The Institute for Genomic Research-Multi Experiment Viewer (MeV) and miRNAs whose expression difference were statistically significant were identified as candidates. The potential target genes of these miRNAs were predicted by miRWalk 2.0 and were functionally enriched by gene ontology (GO) analysis. The expression level of priority candidates was validated by quantitative real-time PCR (qRT-PCR) analysis. We identified ten differentially expressed miRNAs in patients with a fold change threshold ≥ 2.0, FDR = 0. We identified ten differentially expressed miRNAs in patients with a fold change threshold ≥ 2.0, FDR = 0. Nine out of the ten miRNAs were found to be related to top three enriched ALS-related terms. Based on the qRT-PCR validation of candidate miRNAs, patients were separated into two groups: those with upregulated miR-4429 and miR-1825 expression and those with downregulated miR-638 expression. The different muscle-specific miRNA profiles in sALS patients may indicate the involvement of etiologic heterogeneity, which may allow the development of novel therapeutic strategies.
- 9 July 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (6) , 1499-1509
Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALS
Skeletal muscle pathology is thought to have an important role in the onset and/or progression of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by progressive muscle weakness. Since miRNAs are recognized as important regulatory factors of essential biological processes, we aimed to identify differentially expressed miRNAs in the skeletal muscle of sporadic ALS patients through the combination of molecular-omic technologies and bioinformatic tools. We analyzed the miRnome profiles of skeletal muscle biopsies acquired from ten sALS patients and five controls with Affymetrix GeneChip miRNA 4.0 Array. To find out differentially expressed miRNAs in patients, data were analyzed by The Institute for Genomic Research-Multi Experiment Viewer (MeV) and miRNAs whose expression difference were statistically significant were identified as candidates. The potential target genes of these miRNAs were predicted by miRWalk 2.0 and were functionally enriched by gene ontology (GO) analysis. The expression level of priority candidates was validated by quantitative real-time PCR (qRT-PCR) analysis. We identified ten differentially expressed miRNAs in patients with a fold change threshold ≥ 2.0, FDR = 0. We identified ten differentially expressed miRNAs in patients with a fold change threshold ≥ 2.0, FDR = 0. Nine out of the ten miRNAs were found to be related to top three enriched ALS-related terms. Based on the qRT-PCR validation of candidate miRNAs, patients were separated into two groups: those with upregulated miR-4429 and miR-1825 expression and those with downregulated miR-638 expression. The different muscle-specific miRNA profiles in sALS patients may indicate the involvement of etiologic heterogeneity, which may allow the development of novel therapeutic strategies.
- Open Access
- 13 February 2018
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 23 (1) , 5
The altered expression of perineuronal net elements during neural differentiation
Perineuronal nets (PNNs), which are localized around neurons during development, are specialized forms of neural extracellular matrix with neuroprotective and plasticity-regulating roles. Hyaluronan and proteoglycan link protein 1 (HAPLN1), tenascin-R (TNR) and aggrecan (ACAN) are key elements of PNNs. In diseases characterized by neuritogenesis defects, the expression of these proteins is known to be downregulated, suggesting that PNNs may have a role in neural differentiation. In this study, the mRNA and protein levels of HAPLN1, TNR and ACAN were determined and compared at specific time points of neural differentiation. We used PC12 cells as the in vitro model because they reflect this developmental process. On day 7, the HAPLN1 mRNA level showed a 2.9-fold increase compared to the non-differentiated state. However, the cellular HAPLN1 protein level showed a decrease, indicating that the protein may have roles in neural differentiation, and may be secreted during the early period of differentiation. By contrast, TNR mRNA and protein levels remained unchanged, and the amount of cellular ACAN protein showed a 3.7-fold increase at day 7. These results suggest that ACAN may be secreted after day 7, possibly due to its large amount of post-translational modifications. Our results provide preliminary data on the expression of PNN elements during neural differentiation. Further investigations will be performed on the role of these elements in neurological disease models.
- 13 February 2018
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 23 (1) , 5
Open AccessThe altered expression of perineuronal net elements during neural differentiation
Perineuronal nets (PNNs), which are localized around neurons during development, are specialized forms of neural extracellular matrix with neuroprotective and plasticity-regulating roles. Hyaluronan and proteoglycan link protein 1 (HAPLN1), tenascin-R (TNR) and aggrecan (ACAN) are key elements of PNNs. In diseases characterized by neuritogenesis defects, the expression of these proteins is known to be downregulated, suggesting that PNNs may have a role in neural differentiation. In this study, the mRNA and protein levels of HAPLN1, TNR and ACAN were determined and compared at specific time points of neural differentiation. We used PC12 cells as the in vitro model because they reflect this developmental process. On day 7, the HAPLN1 mRNA level showed a 2.9-fold increase compared to the non-differentiated state. However, the cellular HAPLN1 protein level showed a decrease, indicating that the protein may have roles in neural differentiation, and may be secreted during the early period of differentiation. By contrast, TNR mRNA and protein levels remained unchanged, and the amount of cellular ACAN protein showed a 3.7-fold increase at day 7. These results suggest that ACAN may be secreted after day 7, possibly due to its large amount of post-translational modifications. Our results provide preliminary data on the expression of PNN elements during neural differentiation. Further investigations will be performed on the role of these elements in neurological disease models.